/
OKUR
$4.50+$0.00 (+0.00%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$181.8M
40M shares
52-week range
$1.91 – $5.38
75% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
1.15%
Moderate
Price (6 mo)
Loading chart…
Change$-14.15
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $37.0K | $50.0K | $0 | $0 | $0 | $830.0K |
| Gross profit | −$37.0K | −$50.0K | $0 | $0 | $0 | −$830.0K |
| Gross margin | — | — | — | — | — | — |
| R&D | $15.9M | $28.1M | $25.9M | $32.1M | $43.8M | $48.3M |
| Operating income | −$19.6M | −$39.8M | −$29.8M | −$36.9M | −$54.4M | −$63.0M |
| EBITDA | −$19.4M | −$39.7M | −$29.1M | −$34.8M | −$51.7M | −$58.7M |
| Net income | −$19.5M | −$39.8M | −$29.5M | −$35.3M | −$52.7M | −$59.5M |
| Net margin | — | — | — | — | — | — |
| EPS (diluted) | -7.74 | -21.92 | -2.21 | -2.65 | -3.95 | -4.40 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $500000 | $-2.50 | $-2.50–$-2.50 | 2 |
| 2027 | $666667 | $-2.13 | $-2.13–$-2.13 | 2 |
| 2028 | $2M | $-2.10 | $-2.24–$-2.00 | 3 |
| 2029 | $0 | $-1.58 | $-1.58–$-1.58 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$4.23
Price
$4.50
Implied downside
-6%
Peer comparison
OnKure Therapeutics, Inc. Class A Common Stock
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure-based drug design platform to develop a pipeline of drug candidates aimed at optimizing efficacy and tolerability. The company has multiple programs focused on targeting oncogenic PI3Kα. Its flagship program is OKI-219. The company operates in one operating segment: clinical research.
www.onkuretherapeutics.com- Employees
- 45
- IPO / List date
- Oct 7, 2024
- HQ
- BOULDER, CO
Held by traders on TradeandTell
No one on the platform currently holds OKUR.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 377,250 | $1.6M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded OKUR yet.
